Difference between revisions of "Cabozantinib (Cometriq)"

Revision as of 20:39, 29 November 2020

General information

Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.^[1]^[2]^[3]^[4]^[5]^[6]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]^[4]

Diseases for which it is used

Patient drug information

Cabozantinib (Cometriq) package insert pages 20-24^[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
Cabozantinib (Cabometyx) package insert^[4]
Cabozantinib (Cometriq) patient drug information (Chemocare)^[7]
Cabozantinib (Cometriq) patient drug information (UpToDate)^[8]

History of changes in FDA indication

Hepatocellular carcinoma

1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (new disease entity)

Medullary thyroid cancer

11/29/2012: Initial approval (as Cometriq) for treatment of progressive metastatic medullary thyroid cancer (MTC).

Renal cell carcinoma

4/25/2016: Approved (as Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. (new disease entity)
12/19/2017: Granted FDA regular approval for treatment of patients with advanced renal cell carcinoma (RCC). (converted to regular approval; no longer requires prior treatment)

Also known as

Code names: XL184, XL-184
Brand names: Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.

References

[insert-1] 1.0 ^1.1 ^1.2 Cabozantinib (Cometriq) package insert

[2] Cabozantinib (Cometriq) package insert (locally hosted backup)

[3] Cometriq manufacturer's website

[insert_Cabometyx-4] 4.0 ^4.1 ^4.2 Cabozantinib (Cabometyx) package insert

[5] Cabozantinib (Cabometyx) package insert (locally hosted backup)

[6] Cabometyx manufacturer's website

[7] Cabozantinib (Cometriq) patient drug information (Chemocare)

[8] Cabozantinib (Cometriq) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

@@ Line 21: / Line 21: @@
 ==History of changes in FDA indication==
 ===[[Hepatocellular carcinoma]]===
-*1/14/2019: Approved for patients with hepatocellular carcinoma (HCC) who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(new disease entity)''
+*1/14/2019: Approved for patients with [[Hepatocellular carcinoma|hepatocellular carcinoma (HCC)]] who have been previously treated with [[Sorafenib (Nexavar)|sorafenib]]. ''(new disease entity)''
 ===[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]]===
 *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm Initial approval] (as Cometriq) for treatment of progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]].